

PubHive Named Best AI-Driven Pharmacovigilance Platform 2026

PubHive combines Human-in-the-Loop AI-Assisted Review, connected safety workflows, and traceable evidence management for pharmacovigilance.

LONDON, UNITED KINGDOM, September 22, 2026 /EINPresswire.com/ -- [PubHive](#), the award-winning AI-powered SaaS platform company for scientific literature and safety information management, is proud to announce that it has been named "[Best AI-Driven Pharmacovigilance Platform 2026](#)" in the SME Managing Director of the Year Awards.

“

Pharmacovigilance teams need technology that can reduce operational complexity without removing the scientific oversight behind critical safety decisions”

*Raj Vaghela, President & CEO,
PubHive*

The recognition reflects PubHive’s continued focus on helping pharmacovigilance teams manage growing volumes of scientific literature and safety information through more connected, structured, and transparent workflows.

At the centre of this approach is PubHive Navigator™, which brings together literature monitoring, safety review, signal activities, aggregate reporting support, and scientific evidence management within one controlled environment for regulated life sciences teams.

□Connecting Literature with the Wider Safety Workflow

Pharmacovigilance teams must continuously identify, assess, document, and act on relevant safety information. Yet these activities are often distributed across databases, spreadsheets, email alerts, and separate systems, making it harder to maintain consistency and visibility across the complete review process.

PubHive is designed to connect these activities rather than automate them in isolation.

The platform supports global and local literature monitoring, ICSR review, signal detection and management, aggregate reporting workflows, reviewer assignment, quality control, dashboards, and audit-ready traceability within a connected pharmacovigilance environment.

By maintaining evidence, reviewer activity, decisions, and follow-up actions within structured workflows, teams can retain clearer oversight from literature identification through downstream safety activities.

□□ Human-in-the-Loop AI-Assisted Review

A core principle behind PubHive's pharmacovigilance innovation is Human-in-the-Loop AI-Assisted Review.

AI can support literature screening, classification, prioritisation, and evidence assessment, while qualified professionals remain responsible for reviewing outputs and making final safety decisions.



PubHive Named Best AI-Driven Pharmacovigilance Platform 2026

This approach is designed to deliver the efficiency benefits of AI without separating automation from the scientific judgement, transparency, and accountability required in pharmacovigilance.

Key areas include:

- AI-Assisted Safety Review: Supporting screening, classification, and prioritisation while keeping qualified reviewers in control.
- Connected Safety Evidence: Linking literature with ICSR, signal, and aggregate reporting activities within one coordinated workflow.
- Global & Local Oversight: Managing product, country, reviewer, and literature activities through centralised workflows.
- Signal & Aggregate Reporting Support: Connecting reviewed literature evidence with downstream signal management and aggregate safety reporting activities.
- Reviewer Assignment & Quality Control: Supporting structured review ownership, QC steps, accountability, and consistent decision-making.
- Operational Visibility & Deadlines: Tracking review status, pending actions, due dates, and

overdue activities through dashboards.

□ Traceable Decision-Making: Maintaining assessments, comments, reviewer actions, evidence history, and audit trails throughout the review lifecycle.

□ Built Around the Realities of Pharmacovigilance

Purpose-built for regulated life sciences environments, PubHive combines Human-in-the-Loop AI-Assisted Review, workflow automation, and connected safety evidence management to help pharmacovigilance teams manage increasing literature volumes while maintaining expert oversight, traceability, and control.

“Pharmacovigilance teams need technology that can reduce operational complexity without removing the scientific oversight behind critical safety decisions,” said [Raj Vaghela](#), Founder and CEO of PubHive Ltd. “This recognition reinforces our approach at PubHive: combining Human-in-the-Loop AI with connected, traceable workflows that support professionals throughout the safety process. It reflects our team’s continued commitment to responsible innovation and to solving the practical challenges our customers face every day.”

□ From Individual Tasks to Connected Safety Intelligence

PubHive’s development strategy extends beyond improving individual review steps. The company is focused on creating a connected safety ecosystem where evidence can move across literature monitoring, safety assessment, signal management, and reporting without losing context or traceability.

By linking these activities within a shared environment, PubHive helps reduce fragmented hand-offs between teams and creates greater continuity from evidence identification through review, escalation, and downstream safety action. Structured ownership and consistent workflows also help organisations coordinate activities across products, countries, internal teams, affiliates, and external partners.

Centralising evidence and workflow activity gives teams greater visibility into responsibilities, review status, deadlines, open actions, and decision history, while supporting a more governed and scalable approach to pharmacovigilance operations.

□ Advancing Practical AI in Pharmacovigilance

PubHive will continue investing in AI-assisted review, scientific literature intelligence, and connected pharmacovigilance workflows.

Its focus remains on practical applications of Human-in-the-Loop AI that can reduce repetitive activity, help surface relevant evidence, strengthen operational visibility, and support more

efficient safety processes without removing professional oversight.

The Best AI-Driven Pharmacovigilance Platform 2026 recognition reinforces PubHive's commitment to developing connected, configurable, and compliance-ready technology for modern pharmacovigilance operations.

□ About PubHive

PubHive Ltd. is a cloud-based life sciences technology company accelerating automation across pharmaceutical, biotechnology, medical device, and scientific research organisations. Its flagship platform, PubHive Navigator™, brings together pharmacovigilance, Medical Affairs, scientific literature monitoring, evidence management, and regulatory workflows within a secure, AI-powered environment.

By streamlining literature surveillance, safety evidence review, signal management, document delivery, and workflow automation, PubHive helps life sciences teams strengthen collaboration, compliance, and operational efficiency.

Website: <https://pubhive.com>

Book a Demo: <https://pubhive.com/sales>

Media Contact: hello@pubhive.com

□ About the SME Managing Director of the Year Awards

The SME Managing Director of the Year Awards, organised by SME News, recognise business leaders and organisations demonstrating leadership, innovation, and continued development across their respective sectors.

Raj Vaghela

PubHive Ltd

+44 7753 166224

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/944159747>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.